Patrick O'Brien

Experience

• Representative clients include:
• Zai Labs
• IQVIA Holdings, Inc.
• Alexion Pharmaceuticals, Inc.
• Represented the following issuers in their proposed initial public offerings: Zai Labs, IMS Health Holdings, Inc., Aptalis Holdings Inc., Par Pharmaceutical Holdings, Inc., Iasis Healthcare Corporation, and Petco Holdings, Inc. 
• Represented the lead underwriters in initial public offerings and follow on offerings of:
• Moderna, Inc.
• Autolus Therapeutics
• Cushman & Wakefield
• Elanco Animal Health
• AVROBIO, Inc.
• Kiniksa Pharmaceuticals
• Quanterix Corporation 
• Biohaven Pharmaceutical Holdings Company Ltd.
• Clementia Pharmaceuticals Inc.
• CRISPR Therapeutics
• AveXis, Inc.
• Proteostasis Therapeutics, Inc.
• Radius Heath
• bluebird bio, Inc.
• Therapeutics MD
• Dimension Therapeutics, Inc.
• Ocular Therapeutics, Inc.
• Sage Therapeutics, Inc.
• Represented Par Pharmaceutical Holdings, Inc. and Immucor, Inc. in high yield bond offerings. 
• Represented Alexion Pharmaceuticals, Inc. in its $610 million acquisition (plus milestones) of Enobia Inc.
• Represented LA BioMED and UCLA in its sale of a portion of its royalty interest in Kybella. 
• Represented Canadian Pension Plan Investment Board in the purchase of a $168 million royalty interest from Dana Farber Cancer Institute.
• Represented a leading biotechnology company in the sale of its royalty interest in Benlysta to DRI Capital. 
• Represented a publicly traded specialty pharmaceutical company in a complex acquisition and related royalty based financing.
• Represented a university in connection with the sale of a pharmaceutical royalty stream.